REG - Ondine Biomedical - UCL Shows Steriwave Effective Against Mucor Fungus

Ondine BiomedicalAnnouncement

09/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250609:nRSI9015La&default-theme=true

RNS Number : 9015L  Ondine Biomedical Inc.  09 June 2025

9(th) June 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

 

UCL Shows Steriwave Effective Against Mucor Fungus

 

UCL Researchers Present Steriwave Photodisinfection Efficacy Against Dangerous
Mucor Fungus at 19th World Congress of the International Photodynamic
Association in Shanghai, China

 

·   Mucor fungal infections pose a serious risk to immunocompromised
patients, such as those undergoing bone marrow transplants, with mortality
rates often exceeding 50%.

 

Ondine Biomedical Inc. (AIM: OBI) announces new data from University College
London (UCL), demonstrating the potent efficacy of Ondine's Steriwave(®)
photodisinfection technology against the often-lethal fungus Mucor. The
findings were presented in an abstract at the 19th World Congress of the
International Photodynamic Association (IPA) in Shanghai, China.

 

Dr. Colin Hopper and Dr. Aashvi Joshi of University College London, Eastman
Dental Institute, Oral and Maxillofacial Surgery, London, stated:

 

"Fungal infections, especially mucormycosis, are a serious threat in
hospitals, with alarmingly high mortality rates and very few effective
treatment options. The ability of Steriwave to rapidly and safely decolonize
the nose of fungal pathogens represents a major advance in infection
prevention, helping to protect patients from these life-threatening infections
with affordable therapy."

 

Mucor fungal infections, particularly mucormycosis, pose a serious risk to
immunocompromised patients, such as those undergoing bone marrow transplants,
with mortality rates often exceeding 50%. Current therapies for mucormycosis
are limited by high toxicity, incomplete efficacy, the need for aggressive
surgery, frequent treatment failures, and persistently high mortality rates.
These issues highlight the urgent need for new and more effective treatment
strategies for the growing problem of drug-resistant fungal infections.

 

The research, conducted at UCL-where photodisinfection was invented by
Emeritus Professor Michael Wilson in the late 1980s-showed that Ondine's
Steriwave technology was able to completely inhibit the growth of all cells of
Mucor in vitro, with very short treatment times. The results also demonstrated
that Steriwave enhanced activity of other antifungals such as azoles, pointing
the way to a combined topical and systemic approach to treatment of this
invasive and deadly fungus.

 

By providing effective nasal decolonization of Mucor and other fungal
pathogens, Steriwave photodisinfection offers a new approach to reduce patient
risk and improve outcomes for those most vulnerable to invasive fungal
disease. The ability to rapidly and safely eliminate these pathogens from the
nasal passages is especially significant in hospital settings, where nasal
pathogens are a major source of surgical site infections (SSIs) and
healthcare-associated infections (HAIs), and where antimicrobial resistance is
an escalating threat.

 

Ondine's patented Steriwave technology is already in use in hospitals across
Canada and the UK for nasal decolonization to prevent SSIs and HAIs. The new
findings from University College London provide further evidence of
Steriwave's broad-spectrum efficacy and potential to significantly reduce the
burden of healthcare-associated infections worldwide.

 

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFZGGVLRZGKZG